ACRS - Aclaris Therapeutics Inc logo

Aclaris Therapeutics Inc

ACRS
Rev โ€”top 1%10Y
Compare ACRS Hold

Aclaris Therapeutics develops novel drugs for immuno-inflammatory diseases, focusing on monoclonal and bispecific antibodies and kinase inhibitors. Its pipeline includes candidates for conditions like atopic dermatitis, asthma, and autoimmune diseases.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$205today

Score Overview

1 Year
Score
Net Growth-16.66%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth5.02%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.3
Net Growth16.65%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth21.56%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-57.53%
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev Trend70%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-268.32%
Net Trend27%
Net Income Consistency
Rev Growthโ€”
Rev Trend64%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Aclaris Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. ACRS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 5.26โ€”
1 Year2025-09-30
$ 1.90176.84%
5 Years2021-09-30
$ 18.00-70.78%
10 Years2016-09-30
$ 25.61-79.46%
All Time2015-10-07
$ 11.05-52.40%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 8M-$ 75M$ 91M
2025$ 7M-$ 64M$ 90M
2024$ 18M-$ 132M$ 113M
2023$ 31M-$ 88M$ 119M
2022$ 29M-$ 86M$ 217M
2021$ 6M-$ 90M$ 191M
2020$ 6M-$ 51M$ 54M
2019$ 4M-$ 161M$ 75M
2018$ 10M-$ 132M$ 167M
2017$ 1M-$ 68M$ 208M
2016$ 0.00-$ 48M$ 174M
IPO2015$ 0.00-$ 20M$ 92M
ACRS - Aclaris Therapeutics Inc logo

Aclaris Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 6M to $ 7M and net income went from -$ 51M to -$ 64M. Revenue increased in 3 of those 5 years; net income in 2.

Aclaris Therapeutics Inc currently holds a 5-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.

Membership

Explore ACRS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies